Alaunos Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Alaunos Therapeutics Inc.
- Former names
- Ziopharm Oncology Inc Easyweb Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Fort Lauderdale
- Headquarters state / province
- Florida
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- TCRT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001107421
- EIN
- 84-1475642
Board of directors
-
Dale Curtis Hogue Jr. · Director · See RemarksSince 2023
-
Holger Weis · Director · Chief Executive OfficerSince 2023
-
Jaime Vieser · DirectorSince 2023
-
James Huang · DirectorSince 2023
-
Kevin S. Boyle Sr. · Director · Chief Executive OfficerSince 2023
- Since 2023
-
Michael Allen Jerman · DirectorSince 2025
-
Robert Hofmeister · DirectorSince 2023
-
Robert W. Postma · DirectorSince 2023
Chief executives
Since December 2023
Holger Weis
· Chief Executive Officer
Until December 2023
· Former
Kevin S. Boyle Sr.
· Chief Executive Officer
Until December 2023
· Former
Director election results
Annual meeting of July 3, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
100.0%
-
100.0%
-
100.0%
Board connections
5 of this board's directors also sit on 10 other boards.
- via Mary Thistle
- via James Huang
- via James Huang
- via Mary Thistle
- via Mary Thistle
- via Holger Weis
- via Michael Allen Jerman
- via Jaime Vieser
- via Mary Thistle
- via Michael Allen Jerman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 6, 2026 | Holger Weis Officer (CEO) | Grant or award | +4,363 | $2.01 | $8,770 |
| Jul 23, 2026 | Jaime Vieser Director | Grant or award | +8,789 | $1.92 | $16,875 |
| Jul 23, 2026 | Robert W. Postma Director | Grant or award | +8,463 | $1.92 | $16,249 |
| Jul 23, 2026 | Holger Weis Officer (CEO) | Grant or award | +4,568 | $1.92 | $8,771 |
| Jul 23, 2026 | Michael Allen Jerman Director | Grant or award | +8,138 | $1.92 | $15,625 |
| Jun 30, 2026 | Holger Weis Officer (Chief Executive Officer) | Grant or award | +3,880 | $2.26 | $8,769 |
| Jun 12, 2026 | Holger Weis Officer (Chief Executive Officer) | Grant or award | +7,761 | $2.26 | $17,540 |
| May 22, 2026 | Holger Weis Officer (Chief Executive Officer) | Grant or award | +3,700 | $2.37 | $8,769 |
| Apr 29, 2026 | Jaime Vieser Director | Grant or award | +6,515 | $2.59 | $16,874 |
| Apr 29, 2026 | Robert W. Postma Director | Grant or award | +6,274 | $2.59 | $16,250 |
| Apr 29, 2026 | Michael Allen Jerman Director | Grant or award | +6,032 | $2.59 | $15,623 |
| Jan 12, 2026 | Michael Allen Jerman Director | Grant or award | +5,406 | $2.89 | $15,623 |
| Jan 12, 2026 | Robert W. Postma Director | Grant or award | +5,622 | $2.89 | $16,248 |
| Jan 12, 2026 | Jaime Vieser Director | Grant or award | +5,839 | $2.89 | $16,875 |
| Nov 21, 2025 | Jaime Vieser Director | Grant or award | +5,340 | $3.16 | $16,874 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.